Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer

被引:0
作者
Shen, Qiang [1 ]
Murakami, Kiichi [1 ]
Sotov, Valentin [1 ]
Butler, Marcus [1 ,2 ,3 ]
Ohashi, Pamela S. [1 ,4 ,5 ]
Reedijk, Michael [1 ,5 ,6 ]
机构
[1] Univ Hlth Network, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada
[2] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada
[3] Univ Toronto, Dept Med, Div Med Oncol, Toronto, ON, Canada
[4] Univ Toronto, Dept Immunol, Med Sci Bldg,1 Kings Coll Circle,Room 7205, Toronto, ON M5S 1A8, Canada
[5] Univ Toronto, MaRS Ctr, Dept Med Biophys, Toronto Med Discovery Tower,101 Coll St,Room 15-70, Toronto, ON M5G 2M9, Canada
[6] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Surg Oncol, 610 Univ Ave,Suite 8-411, Toronto, ON M5G 2M9, Canada
基金
加拿大健康研究院;
关键词
TUMOR-ASSOCIATED MACROPHAGES; SIGNALING PATHWAY; CELLS; INFLAMMATION; NIVOLUMAB; THERAPY; INVASIVENESS; EXPRESSION; MICROENVIRONMENT; PEMBROLIZUMAB;
D O I
10.1126/sciadv.ado8275
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Aberrant Notch, which is a defining feature of triple-negative breast cancer (TNBC) cells, regulates intercellular communication in the tumor immune microenvironment (TIME). This includes tumor-associated macrophage (TAM) recruitment through Notch-dependent cytokine secretion, contributing to an immunosuppressive TIME. Despite the low response rate of TNBC to immune checkpoint blockade (ICB), here, we report that inhibition of Notch-driven cytokine-mediated programs reduces TAMs and induces responsiveness to sequentially delivered ICB. This is characterized by the emergence of GrB+ cytotoxic T lymphocytes (CTLs) in the primary tumor. A more impressive effect of sequential treatment is observed in the lung where TAM depletion and increased CTLs are accompanied by near-complete abolition of metastases. This is due to (i) therapeutic reduction in Notch-dependent, prometastatic circulating factors released by the primary tumor, and (ii) elevated PD ligand 1 (PD-L1) in lung metastases, rendering them profoundly sensitive to ICB. These findings highlight the potential of combination cytokine inhibition and ICB as an immunotherapeutic strategy in TNBC.
引用
收藏
页数:14
相关论文
共 50 条
[21]   Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges [J].
Uchimiak, Katarzyna ;
Badowska-Kozakiewicz, Anna M. ;
Sobiborowicz-Sadowska, Aleksandra ;
Deptala, Andrzej .
CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022, 16
[22]   PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim [J].
Byerly, Jessica H. ;
Port, Elisa R. ;
Irie, Hanna Y. .
BREAST CANCER RESEARCH, 2020, 22 (01)
[23]   Methylseleninic Acid Enhances Paclitaxel Efficacy for the Treatment of Triple-Negative Breast Cancer [J].
Qi, Yanfeng ;
Fu, Xueqi ;
Xiong, Zhenggang ;
Zhang, Haitao ;
Hill, Steven M. ;
Rowan, Brian G. ;
Dong, Yan .
PLOS ONE, 2012, 7 (02)
[24]   Targeted inhibition of Notch1 gene enhances the killing effects of Paclitaxel on triple-negative breast cancer cells [J].
Zhou, Yu-Fu ;
Sun, Qian ;
Zhang, Ya-Jun ;
Wang, Geng-Ming ;
He, Bin ;
Qi, Tao ;
Zhou, Yan ;
Li, Xing-Wang ;
Li, Sheng ;
He, Lin .
ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2017, 10 (02) :172-176
[25]   Icaritin enhances the efficacy of cetuximab against triple-negative breast cancer cells [J].
Yin, Li ;
Qi, Xiao-Wei ;
Liu, Xun-Zhou ;
Yang, Ze-Yu ;
Cai, Rui-Li ;
Cui, Hong-Juan ;
Chen, Li ;
Yu, Shi-Cang .
ONCOLOGY LETTERS, 2020, 19 (06) :3950-3958
[26]   LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer [J].
Li, Mengxing ;
Viswanadhapalli, Suryavathi ;
Santhamma, Bindu ;
Pratap, Uday P. ;
Luo, Yiliao ;
Liu, Junhao ;
Altwegg, Kristin A. ;
Tang, Weiwei ;
Liu, Zexuan ;
Li, Xiaonan ;
Ebrahimi, Behnam ;
Yan, Hui ;
Zou, Yi ;
Konda, Swapna ;
Sareddy, Gangadhara R. ;
Xu, Zhenming ;
Chen, Yidong ;
Rao, Manjeet K. ;
Brenner, Andrew J. ;
Kaklamani, Virginia G. ;
Tekmal, Rajeshwar R. ;
Ahmed, Gulzar ;
Raj, Ganesh, V ;
Nickisch, Klaus J. ;
Nair, Hareesh B. ;
Vadlamudi, Ratna K. .
COMMUNICATIONS BIOLOGY, 2021, 4 (01)
[27]   Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors [J].
Chen, Xin-Yu ;
Li, Bin ;
Wang, Ye ;
Jin, Juan ;
Yang, Yu ;
Huang, Lei-Huan ;
Yang, Meng-Di ;
Zhang, Jian ;
Wang, Bi-Yun ;
Shao, Zhi-Ming ;
Ni, Ting ;
Huang, Sheng-Lin ;
Hu, Xi-Chun ;
Tao, Zhong-Hua .
CANCER COMMUNICATIONS, 2023, 43 (09) :1003-1026
[28]   A review of immune checkpoint blockade in breast cancer [J].
Pellegrino, Benedetta ;
Tommasi, Chiara ;
Cursio, Olga Elisabetta ;
Musolino, Antonino ;
Migliori, Edoardo ;
De Silva, Pushpamali ;
Senevirathne, Thilini Hemali ;
Schena, Marina ;
Scartozzi, Mario ;
Farci, Daniele ;
Willard-Gallo, Karen ;
Solinas, Cinzia .
SEMINARS IN ONCOLOGY, 2021, 48 (03) :208-225
[29]   Breaking Barriers: The Promise and Challenges of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer [J].
Said, Sawsan Sudqi ;
Ibrahim, Wisam Nabeel .
BIOMEDICINES, 2024, 12 (02)
[30]   Carrier-Free Photodynamic Bioregulators Inhibiting Lactic Acid Efflux Combined with Immune Checkpoint Blockade for Triple-Negative Breast Cancer Immunotherapy [J].
Chen, Guimei ;
Lin, Ling ;
Mai, Ziyi ;
Tang, Yan ;
Zhang, Qiaoling ;
Chen, Gui ;
Li, Zibo ;
Zhang, Jiasi ;
Wang, Yongxia ;
Yang, Yuanyuan ;
Yu, Zhiqiang .
ACS NANO, 2024, 18 (30) :19875-19889